{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 126,
  "pageCount": 239,
  "prevPage": 125,
  "nextPage": 127,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a testimonial from a former employee to undermine the credibility of the company's historical clinical trial success.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/126",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-126",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "But this all worked because the data they were selling was based on choosing the exact patients they wanted. A lot of it was just biased. It wasn’t real-world data.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b341-3b42a2338e5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "One of Nevro’s most tenured district sales managers... offered a detailed account of Nevro’s trajectory and current plight... He began by describing Nevro’s launch: “the easiest sale ever because everyone wanted to try this paresthesia-free stimulator”, with the company quickly getting to 15% share of the SCS market. Then he explained that “this all worked” because Nevro was selling “biased” data that “wasn’t real world.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae59a055-42d4-4bf6-8968-7fd0016420cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.88,
        "x": 0.06,
        "y": 0.38
      },
      "kind": "quote",
      "text": "“Nevro changed the entire dynamic of the spinal cord stim industry... It was the best data that we’ve seen... It was the easiest sale ever... So let’s go back to 2015... But this all worked because the data they were selling was based on choosing the exact patients they wanted. A lot of it was just biased. It wasn’t real-world data.” – Former Nevro district sales manager, now at a key competitor",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3eb87933-5511-42bc-b77c-64280b2504f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“the easiest sale ever because everyone wanted to try this paresthesia-free stimulator” — Former Nevro district sales manager; “this all worked” — Former Nevro district sales manager; “Nevro changed the entire dynamic of the spinal cord stim industry. They created excitement. It was the first company to do a head-to-head level one RCT study against the competitor and their data was remarkable. It was the best data that we’ve seen and so, that’s one of the main reasons I went there. There were doctors that were reaching out to me—it was the easiest sale ever, because everyone wanted to try this paresthesia-free stimulator that sort of crushed axial, back, and leg pain. The only thing I had to bring in was the stim and it sold itself.” — Former Nevro district sales manager; “So let’s go back to 2015. We’re growing. The trials always did very well with Nevro and with HF10 and across the board, trials typically do very well in this industry because it’s sort of like the patients get this burst of: “Wow! Pain relief.” It’s remarkable, right? They only have this for seven days and, you know, the representatives, they’re reaching out to them, they make sure everything is going well, so the trials always did very, very well at Nevro.” — Former Nevro district sales manager; “We went up to around 15% of the market. But this all worked because the data they were selling was based on choosing the exact patients they wanted. A lot of it was just biased. It wasn’t real-world data.” — Former Nevro district sales manager",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b341-3debde39d8a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4dfe80b1-66af-4c35-abca-43a06eee2dfe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.88,
        "x": 0.06,
        "y": 0.1
      },
      "kind": "title",
      "text": "9. Nevro’s current predicament – a one-tick pony stuck in a ditch – and drivers of its ongoing growth collapse",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2df014e-8813-4268-af6d-ed3005636768",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd150166-de82-4638-957b-ab8911eb1af4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "3d79026e-b850-49b9-a567-19c134991948",
      "evidence": "The slide explicitly frames the company's success as a result of 'biased' data and 'not real-world' results to expose a contradiction in their market performance.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}